Clinical review pending. This article has not yet been reviewed by a licensed clinician, and we would rather say so than print a name that does not exist.

Patients ask about peptides by name, and staff hear the word every week. For a practice, the useful question is not a definition contest. It is whether a specific therapy has a lawful way to reach a patient, through which kind of pharmacy, and with what documentation.

This primer is general information for licensed clinicians and practice owners. It is not legal advice, and it names no products.

The word is not a legal status

The word peptide is a chemistry label for a kind of molecule. That label is not a health claim. It says nothing about whether a substance is an FDA-approved drug, an eligible ingredient for a patient-specific preparation, a dietary supplement, or a "research use only" chemical that should not reach a patient.

Some approved medicines are peptides. Many substances patients hear about online are not approved drugs and have no current pathway through a pharmacy that compounds for a patient. The same word covers both. That is why "is it a peptide?" is the wrong first question for a practice.

Four questions that decide the pathway

Before a practice adds a therapy in this category, its clinicians and its pharmacy partner should be able to answer these.

  1. Is the substance eligible at all? Under federal law, a 503A pharmacy may compound from a bulk substance only if it meets a statutory criterion, such as a USP monograph, a component of an approved drug, or inclusion on FDA's 503A bulks list. While it evaluates nominated substances, FDA publishes interim categories under its guidance. Those categories reflect FDA enforcement policy, not statute, and FDA can change them.
  2. Is it essentially a copy of a commercially available drug? A 503A pharmacy may not compound essentially copies of a commercially available drug regularly or in inordinate amounts. The exception is a change that the prescriber determines makes a significant difference for the patient. FDA's guidance asks that this be noted on the prescription.
  3. Which kind of pharmacy, and for whom? A 503A pharmacy compounds for an identified patient on a valid prescription. A registered 503B outsourcing facility may supply office stock without a patient-specific prescription. When that facility prepares from a bulk substance, the substance must be on FDA's 503B bulks list or used to address a drug on FDA's shortage list. FDA applies an interim policy while it builds the 503B list.
  4. What does your state allow in the office? In Virginia, a 503A pharmacy may provide office stock only for an emergency or as federal law allows, so routine office stock from a 503A pharmacy is not a pathway. A patient-specific prescription delivered to a practice has its own permit and contract requirements. See in-office administration: the Virginia rules.

If any answer is "not sure," the therapy is not ready for your practice yet.

These preparations are not FDA-approved

Drugs a pharmacy compounds are not FDA-approved. As FDA puts it, FDA does not verify their safety, effectiveness, or quality before they are marketed. A practice should not say or imply that such a drug is approved, generic, or equivalent to or better than an approved drug.

Federal policy is moving

On October 14, 2026, FDA submitted a notice to the White House Office of Management and Budget for review. The notice is RIN 0910-ZD94. As of October 20, 2026, it had not been published. Until the text is public, nothing changes for practices, and nothing should be presented to patients as newly available.

Red flags for any source

  • "Research use only" or "not for human consumption" on anything offered to a clinic.
  • No state pharmacy license you can verify. For a 503B facility, no listing on FDA's registered outsourcing facilities page. FDA also posts inspection findings and warning letters, which you can check.
  • No certificate of analysis by lot.
  • Offers of free goods, rebates, or payments tied to prescribing.

How SiriusRx helps

Sirius Peptides, by SiriusRx, gives your practice managed ordering through several licensed partner pharmacies. Your prescriber decides every order. Contact us to ask what the platform covers. We do not present anything as available before it has a documented, lawful pathway.

General information, not legal advice.

Sources

For practices

Contact us.